Axon Enterprise (AXON) Drops -30.7% Over 30 Days as Margin and Dilution Worries Take Hold
Key Takeaways
- Axon Enterprise shares declined roughly 30.7% over the past 30 days, from a closing price of $645.72 on August 19, 2026, to $447.76 on September 18, 2026.
- The selloff followed a strong Q2 2026 earnings report, as investors focused instead on contracting margins, expiring tariff credits, and the removal of cash-flow guidance.
- A $1 billion zero-coupon convertible note offering announced in mid-September amplified dilution concerns and renewed scrutiny of near-term free cash flow.
- Despite the pullback, the stock remains modestly higher over the trailing three months, having surrendered gains after an intraday peak of $651.61 on August 19.
- Rising Treasury yields compounded pressure on a premium valuation that left limited room for execution missteps.
Understanding Axon Enterprise’s Business and Market Position
Axon Enterprise (AXON) stands out as a key player in public safety and law enforcement technology. Its offerings include TASER devices, body-worn cameras, and cloud-based software such as Evidence.com along with the AI Era plan. Recent acquisitions have added counter-drone capabilities via the Dedrone brand, emergency communications through Axon 911, and broader enterprise and federal security solutions.
The company maintains a strong foothold in the U.S. state and local public safety sector, with management estimating about 15% penetration into a roughly $159 billion addressable market. I follow the name closely for its recurring software revenue stream, growing international and enterprise presence, and extended government contracts, while keeping an eye on how its premium valuation stacks up against margin and execution risks.
Stock Performance: The Last 30 Days Compared with the Quarter
Over the most recent 30 days, AXON shares fell about 30.7%, moving from a close of $645.72 on August 19, 2026, to $447.76 on September 18, 2026. The drop picked up speed in September, with the stock sliding roughly 22% as broader pressure hit growth-oriented names.
Looking back over the full quarter, the picture is more mixed. The shares climbed sharply through the summer from around $423 in mid-June to an intraday peak of $651.61 on August 19. Even after the recent decline, the stock sits roughly 5% higher over the trailing three months. On a longer view, shares remain well below the 52-week high of $792.
What Pressured the Stock in the Past Month
The latest leg lower came after the mid-September announcement of a $1 billion zero-coupon convertible senior notes offering due 2031. Shares dropped about 9.8% on the news, ranking among the weakest performers in the S&P 500 that day. The company anticipated roughly $986 million in net proceeds, with about $99.9 million earmarked for capped-call transactions to help contain dilution. Still, the market reacted negatively, viewing the move as a sign of softer near-term cash generation; free cash flow was essentially breakeven in Q2 as inventory was built to meet demand and ease supply-chain concerns.
Those worries echoed themes from the Q2 2026 results released in early August. Revenue came in at about $904 million, up 35% year over year, while annual recurring revenue rose 39% to roughly $1.6 billion and contracted backlog grew 41% to $15.1 billion. Management lifted full-year revenue growth guidance to a 32%–34% range. Yet the shares fell after hours as adjusted gross margin eased from 63.3% to 62.9%, software and services margin declined from 78.9% to 75.1%, and the company withdrew its operating and free cash flow guidance. Management also noted that the third quarter would face higher memory costs and would not benefit from the tariff refunds that supported Q2 results. I checked recent patterns using Tickeron’s AI Pattern Search Engine to see how similar setups have played out.
Broader market conditions added to the pressure. Rising 10-year Treasury yields amid a global bond selloff weighed on high-multiple growth stocks, and AXON’s elevated valuation, which had traded at a premium to peers, offered little buffer.
Performance Drivers Over the Trailing Quarter
Across the past three months, the story centered on solid operational momentum followed by valuation compression. The company posted its tenth straight quarter of revenue growth above 30%, fueled by record TASER 10 demand, a 20% increase in gross bookings, and roughly threefold year-over-year growth in international and enterprise bookings. Analyst support stayed steady, with Barclays lifting its price target to $688, Needham holding at $750, and Argus raising its target to $600; the consensus target remained well above $700.
Even so, the sharp August rally left the stock priced for near-perfect execution. Once margin guidance softened and cash-flow visibility faded, the premium multiple became a drawback. The convertible note offering and higher yields then accelerated the re-rating, even as the underlying business kept expanding.
Key Factors to Monitor Ahead
Several elements are likely to influence AXON near term. The next quarterly report will draw close attention, with consensus estimates pointing to earnings of about $1.94 per share and revenue of roughly $935 million. Focus will center on whether gross margins hold steady amid memory-cost pressures and the lack of tariff credits, and whether free cash flow improves as inventory normalizes.
Progress in newer areas such as the AI Era plan, Dedrone systems, Axon 911, and international and enterprise deployments will also matter. Regulatory views on surveillance and AI tools, municipal budget trends, and the direction of interest rates could affect the valuation multiple. These items should be tracked alongside management’s longer-term goal of roughly $6 billion in annual revenue by 2028.
Exploring AI Tools for Market Context
When reviewing names like this one during periods of volatility, I sometimes turn to Tickeron’s AI Trading Bots for additional perspective on how different strategies are performing across market conditions. The platform’s selection of bots spans various timeframes and approaches, which helps put recent price action into a broader, data-driven frame without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
AXON's RSI Indicator climbs out of oversold territory
The RSI Indicator for AXON moved out of oversold territory on September 16, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 24 of the 26 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 282 of 377 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 55 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on August 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 29 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
AXON moved below its 50-day moving average on September 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AXON crossed bearishly below the 50-day moving average on September 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for AXON entered a downward trend on September 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.901) is normal, around the industry mean (6.438). AXON has a moderately high P/E Ratio (186.567) as compared to the industry average of (59.605). Projected Growth (PEG Ratio) (2.054) is also within normal values, averaging (2.578). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.155).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement